Stockreport

Ionis stock jumps as MASH drug succeeds in mid-stage trial [Seeking Alpha]

Ionis Pharmaceuticals, Inc.  (IONS) 
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ionispharma.com
PDF ION224 is an investigational DGAT2 antisense inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The drug met the p [Read more]